Morgan Stanley Elevates UnitedHealth (UNH) Stock to Top Pick Before Q1 Results

Key Takeaways

• Erin Wright from Morgan Stanley reaffirmed a Buy stance on UNH, setting a $375 price objective
• UNH designated as Wright’s preferred selection amid strengthening managed care outlook
• Updated Medicare Advantage rate guidance provides enhanced clarity for 2026 payment structures
• First-quarter financial results scheduled for April 21; analysts project EPS of $6.60 versus prior-year $7.20
• Bernstein SocGen maintains Outperform position with $411 valuation target for UNH

Morgan Stanley enters UnitedHealth’s quarterly earnings period with strong bullish sentiment. Erin Wright, the firm’s analyst, confirmed her Buy recommendation alongside a $375 valuation objective, simultaneously designating UnitedHealth as her preferred selection within managed care coverage.

UnitedHealth Group Incorporated, UNH

This endorsement follows a challenging period for the healthcare giant’s shares. Concerns surrounding Medicare Advantage performance and medical expense uncertainty have pressured UNH’s valuation. Wright contends these obstacles are beginning to diminish.

A primary catalyst for her strengthened outlook involves the finalized Medicare Advantage rate announcement. This disclosure delivered improved transparency regarding 2026 payment frameworks and validated projections that UNH can sustain MA margin enhancement.

Wright maintains close observation of the Optum Health restructuring initiative. Following struggles within this division, she identifies increasing evidence that operations are progressing favorably.

She additionally highlighted artificial intelligence-powered operational improvements as a developing positive factor. While still nascent, Wright anticipates UnitedHealth’s technology infrastructure could substantially enhance operational performance long-term.

Q1 Earnings on April 21

UNH delivers first-quarter financial disclosures on Tuesday, April 21. Wright anticipates results largely aligned with projections, without significant deviations.

Analyst consensus forecasts Q1 revenue reaching $109.52 billion, marginally below the $109.58 billion recorded during last year’s comparable quarter. Earnings per share expectations stand at $6.60, down from $7.20 year-over-year.

Market participants will scrutinize Medicare Advantage margin performance, medical expense developments, and management’s perspective on Optum Health’s turnaround progress. Artificial intelligence efficiency advancements and full-year guidance will command additional attention.

UNH presently exchanges hands at $316.40. Based on current pricing, Morgan Stanley’s $375 objective represents approximately 18.5% appreciation potential.

Bernstein Adds Its Voice

Bernstein SocGen exhibits even greater optimism. Lance Wilkes, the firm’s analyst, confirmed an Outperform assessment with a $411 valuation target, characterizing UNH’s current pricing as compelling.

The research house anticipates broader industry improvement as Medicare Advantage profitability rebounds from底部 levels following rate pressures and competitive market exits.

Bernstein additionally identifies company-specific margin enhancement opportunities as UNH discontinues underperforming MA and Optum Health offerings. The firm forecasts robust earnings per share expansion across the upcoming four-year horizon.

The equity trades at a price-to-earnings multiple of 24. For perspective, the consensus Wall Street valuation target spanning 18 Buy ratings and 5 Hold ratings registers at $366.24 — suggesting approximately 15.75% upside potential from present levels.

One notable concern: Leerink identified that UNH confronts heightened exposure to expanded RADV compliance reviews conducted by CMS. Sixty agreements encompassing 92% of Medicare Advantage enrollment face examination — substantially elevated from zero in 2018. These audits commenced processing during April 2025.

UBS recently incorporated UNH into its Global High-Quality Dividend Stock List, recognizing the company as a dependable dividend provider.

The post Morgan Stanley Elevates UnitedHealth (UNH) Stock to Top Pick Before Q1 Results appeared first on Blockonomi.